KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Progyny (PGNY) EBITDA (2018 - 2025)

Progyny (PGNY) has disclosed EBITDA for 8 consecutive years, with $33.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA changed N/A to $33.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $103.7 million, a N/A change, with the full-year FY2025 number at $85.3 million, up 2.49% from a year prior.
  • EBITDA was $33.6 million for Q4 2025 at Progyny, up from $21.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $33.6 million in Q4 2025 to a low of -$188000.0 in Q4 2021.
  • A 5-year average of $14.4 million and a median of $13.8 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 116.19% in 2021, then surged 25981.03% in 2023.
  • Progyny's EBITDA stood at -$188000.0 in 2021, then soared by 1858.51% to $3.3 million in 2022, then skyrocketed by 317.42% to $13.8 million in 2023, then dropped by 9.72% to $12.5 million in 2024, then skyrocketed by 169.78% to $33.6 million in 2025.
  • Per Business Quant, the three most recent readings for PGNY's EBITDA are $33.6 million (Q4 2025), $21.5 million (Q3 2025), and $24.4 million (Q2 2025).